canadian compounding pharmacy semaglutide Compound Drugmakers and pharmacists battle over

GLP-1 receptor agonists, medications that mimic natural appetite-regulating hormones, represent an emerging therapeutic option for managing this clinical challenge

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND trial)

Rocha RI, Junior WC, Modolin MLA, Takahashi GG, Caldini ETEG, Gemperli R

On average, studies show most people living with obesity lose between 15% and 25% of their body weight after just one year on a GLP-1

A comparison of the efficacy of reducing the signs of ageing in the neck skin after polynucleotides injections in regimens with different dosing intervals a case study

doi: 10.1111/acel.12219 90 HoongCWSChuaMWJ